ARQT vs TT · rev $196.5M vs P/E 36, rev $21.32B
Arcutis Biotherapeutics Inc (ARQT) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Latest reported ARQT revenue for 2024-12-31 was $196.5M. Net income was -$140.0M. Revenue was up 229.7% from 2023-12-31 to 2024-12-31. ARQT currently screens at market cap $1.64B.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
ARQT currently screens at market cap $1.64B. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the ARQT and TT stock pages for the full models.
Not investment advice.